Grit Biotechnology

This early-stage study tests a new treatment called GT719 for people with severe neurological autoimmune diseases that have not responded to standard therapies. The treatment uses specially designed cells to target the immune system's attack on the brain and nerves. The study wil…

This early-phase study tests a new treatment called GT101 for adults with solid tumors that have spread or come back. The therapy uses immune cells taken from the patient's own tumor, multiplied in a lab, and then given back along with chemotherapy and immune-boosting drugs. The …

This study tests a new treatment called GT719 for adults with certain blood cancers (B-cell lymphoma or leukemia) that have come back or not responded to standard therapy. The treatment uses specially engineered immune cells to target and attack cancer cells. The trial will enrol…

This study tests a treatment called GT307, made from a patient's own immune cells that are taken from their tumor, grown in a lab, and given back to fight the cancer. It is for adults with advanced solid tumors, specifically ovarian cancer that has returned or not responded to fi…

This study tests a new treatment called GT307, which uses a patient's own immune cells (tumor-infiltrating lymphocytes) to fight advanced solid tumors. About 18 adults who have not responded to standard treatments will receive this personalized cell therapy. The main goal is to c…

This early-phase trial tests an injection called GT719 in 10 people with moderate to severe autoimmune diseases that haven't responded to other treatments. The main goal is to check safety and find the right dose. Researchers will also look for signs that the treatment helps cont…

This early-stage study tests a new treatment called GT719 for adults with certain blood cancers (B-cell lymphoma or leukemia) that have come back or not responded to standard therapy. The treatment uses specially engineered immune cells that are made from a healthy donor, so they…

This early study tests a new treatment for advanced head and neck cancer that has come back or spread. It uses a patient's own immune cells (called TILs) grown in a lab and given back along with a drug that helps the immune system attack the tumor. The main goal is to check safet…

This study tests a new treatment called GT101, made from a patient's own immune cells that attack tumors. It is for people with cervical cancer that has come back or spread. The trial compares GT101 to a standard chemotherapy drug (gemcitabine) to see which works better at slowin…

This study tests an experimental therapy called GT201, made from a patient's own tumor-fighting immune cells (TILs), for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it can shrink tumors. About 18 adu…

This early-stage study tests an injection called GT719 in 30 people with moderate to severe autoimmune diseases like lupus that haven't improved with standard treatments. The main goal is to check safety and find the right dose. Researchers will also look for signs that the treat…

This early-phase study tests a personalized cell therapy (TIL injection) for people with advanced solid tumors that have spread or come back. About 12 adults will receive their own immune cells, grown in a lab, after a short course of chemotherapy. The main goal is to check safet…

This early-stage study tests a new treatment called GT801 in 28 adults with certain blood cancers (like leukemia and lymphoma) or an autoimmune blood disorder (AIHA) that have not responded to standard therapies. The goal is to see if the treatment is safe and can shrink tumors o…

This early-stage study tests a new cell therapy called GT729 for people with chronic graft-versus-host disease (cGVHD) that hasn't improved with standard treatments. cGVHD is a condition where donor immune cells attack the patient's body after a stem cell transplant. The study wi…

This early-stage trial tests a new treatment called IB-T101 for adults with advanced clear cell kidney cancer. The treatment uses a patient's own immune cells (TILs) to fight the cancer. The study aims to see if it is safe and whether it can shrink tumors. Only 12 people will tak…

This study tests a new treatment called GT307, which uses immune cells taken from a patient's own tumor to fight advanced colorectal cancer. The goal is to see if it is safe and can shrink tumors. About 18 adults whose cancer has worsened after first-line chemotherapy will take p…

This early-stage trial tests a new treatment called GT801 for people with moderate-to-severe autoimmune diseases that haven't improved with standard therapies. The study will enroll 22 participants to check safety and how well the treatment works. Researchers will monitor side ef…